Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Scinai Immunotherapeutics ( (SCNI) ) has shared an update.
On September 2, 2025, Scinai Immunotherapeutics reported its financial results for the first half of 2025, highlighting a significant increase in revenues to $773 thousand from $284 thousand in the same period of 2024, driven by the growth of its CDMO business. The company also reduced its R&D expenses and strengthened its cash position by raising $4.2 million in July and August 2025. Scinai’s strategic initiatives include advancing its anti-IL-17 NanoAb program and filing patents for new NanoAbs, while also exploring acquisition opportunities and grant funding to support its development projects. These efforts are expected to enhance Scinai’s industry positioning and offer potential benefits to stakeholders.
Spark’s Take on SCNI Stock
According to Spark, TipRanks’ AI Analyst, SCNI is a Neutral.
Scinai Immunotherapeutics is undergoing a financial recovery but faces significant challenges such as negative cash flows and high debt levels. The stock shows neutral technical indicators, suggesting moderate market confidence. Its attractive valuation might appeal to value investors, but the absence of dividends and financial risks may deter more conservative investors.
To see Spark’s full report on SCNI stock, click here.
More about Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company that operates in two main areas: the development of biological therapeutic products for inflammation and immunology-related diseases, and providing contract development and manufacturing organization (CDMO) services. The company focuses on innovative VHH antibody fragments (nanoAbs) targeting diseases with significant unmet medical needs, and offers services such as drug development, clinical manufacturing, and trial design.
Average Trading Volume: 1,446,131
Technical Sentiment Signal: Sell
Current Market Cap: $1.31M
For detailed information about SCNI stock, go to TipRanks’ Stock Analysis page.